Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TBPH Theravance Biopharma Inc
- Stocks
- Healthcare
- NASDAQ: TBPH
Price (delayed)
$11.01
Market cap
$550.51M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.18
Enterprise value
$487.22M
Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to create transformational medicines to improve the lives
Highlights
The gross profit has grown by 6% YoY
TBPH's revenue is up by 6% year-on-year
Theravance Biopharma's EPS has decreased by 34% YoY and by 2.6% QoQ
The net income has contracted by 30% YoY and by 3.4% from the previous quarter
Key stats
What are the main financial stats of TBPH
Market
Valuations
Earnings
Shares outstanding
50M
Market cap
$550.51M
Enterprise value
$487.22M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.28
Price to sales (P/S)
8.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.47
Revenue
$65.27M
Gross profit
$65.27M
Operating income
-$50.18M
Net income
-$58.33M
EBIT
-$45.79M
EBITDA
-$39.82M
Free cash flow
$32.29M
Per share
Balance sheet
Liquidity
EPS
-$1.18
EPS diluted
-$1.18
Free cash flow per share
$0.65
Book value per share
$3.36
Revenue per share
$1.31
TBVPS
$6.91
Total assets
$343.58M
Total liabilities
$177.6M
Debt
$48.16M
Equity
$165.98M
Working capital
$118.76M
Debt to equity
0.29
Current ratio
4.77
Quick ratio
4.67
Net debt/EBITDA
1.59
Margins
Efficiency
Dividend
EBITDA margin
-61%
Gross margin
100%
Net margin
-89.4%
Operating margin
-76.9%
Return on assets
-16.5%
Return on equity
-32.4%
Return on invested capital
-14.4%
Return on capital employed
-14.7%
Return on sales
-70.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TBPH stock price
How has the Theravance Biopharma stock price performed over time
Intraday
-0.99%
1 week
20.33%
1 month
6.17%
1 year
27.58%
YTD
17%
QTD
23.29%
Financial performance
How have Theravance Biopharma's revenue and profit performed over time
Revenue
$65.27M
Gross profit
$65.27M
Operating income
-$50.18M
Net income
-$58.33M
Gross margin
100%
Net margin
-89.4%
The net income has contracted by 30% YoY and by 3.4% from the previous quarter
Theravance Biopharma's net margin has decreased by 23% YoY and by 2.1% QoQ
The operating income is down by 19% YoY and by 7% QoQ
Theravance Biopharma's operating margin has decreased by 12% YoY and by 5% QoQ
Price vs fundamentals
How does TBPH's price correlate with its fundamentals
Growth
What is Theravance Biopharma's growth rate over time
Valuation
What is Theravance Biopharma stock price valuation
P/E
N/A
P/B
3.28
P/S
8.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.47
Theravance Biopharma's EPS has decreased by 34% YoY and by 2.6% QoQ
The price to book (P/B) is 37% higher than the last 4 quarters average of 2.4
TBPH's equity is down by 19% year-on-year and by 5% since the previous quarter
The P/S is 29% lower than the 5-year quarterly average of 11.9 but 25% higher than the last 4 quarters average of 6.7
TBPH's revenue is up by 6% year-on-year
Efficiency
How efficient is Theravance Biopharma business performance
The ROE has plunged by 71% YoY and by 9% from the previous quarter
The ROIC has plunged by 50% YoY and by 17% from the previous quarter
The company's return on assets fell by 49% YoY and by 6% QoQ
Theravance Biopharma's return on sales has decreased by 24% YoY and by 8% QoQ
Dividends
What is TBPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TBPH.
Financial health
How did Theravance Biopharma financials performed over time
Theravance Biopharma's total assets is 93% more than its total liabilities
TBPH's current ratio is down by 17% year-on-year and by 5% since the previous quarter
The company's quick ratio fell by 12% YoY and by 4.9% QoQ
Theravance Biopharma's debt is 71% lower than its equity
The debt to equity rose by 26% YoY and by 3.6% QoQ
TBPH's equity is down by 19% year-on-year and by 5% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.